STOCK TITAN

Cutera Inc - CUTR STOCK NEWS

Welcome to our dedicated page for Cutera news (Ticker: CUTR), a resource for investors and traders seeking the latest updates and insights on Cutera stock.

Overview of Cutera Inc

Cutera Inc is a pioneering company in laser technology and medical aesthetics that designs, develops, manufactures, markets, and services a comprehensive range of energy-based medical aesthetic systems. Renowned for its advanced ND:YAG technology, Cutera offers safe and effective treatment solutions that are used by medical professionals globally to address a variety of aesthetic concerns including skin resurfacing, acne treatment, body contouring, and hair removal. The company has earned a reputation as a trusted authority in the aesthetic device industry by consistently delivering state-of-the-art products that integrate innovation, sophistication, and performance.

Innovative Technology and Product Portfolio

Cutera's success is built upon its commitment to advancing laser and optical engineering. At its core, the company develops high-performance devices that harness energy to produce precise outcomes for various medical aesthetic procedures. Its portfolio includes a collection of premium products designed around the needs of the medical aesthetic community, enabling clinicians to deliver faster and safer procedures. With a focus on energy-based modalities, Cutera champions breakthrough technologies that combine picosecond, nanosecond, and dual-wavelength systems to enhance safety and efficacy in treatments.

Business Model and Market Presence

The company primarily derives its revenue through the direct sale and servicing of its innovative devices, backed by a strong network of operations in North America and multiple key international markets. Cutera maintains a significant market presence by continually updating its product offerings to match evolving clinical needs, and by keeping its focus on regulatory compliance and performance excellence. Its operations are built on a model that emphasizes customer support, ongoing clinical education, and product reliability, ensuring practitioners can trust the devices’ performance on a global scale.

Operational Excellence and Industry Position

Cutera sets itself apart by not only offering cutting-edge technology but also instilling confidence in practitioners through balanced design and effective usability. The company focuses on developing solutions that ensure better results through carefully designed energy-based systems. This process is supported by a deep understanding of anatomical nuances and treatment protocols, making its products highly adaptable across various clinical applications. Such operational excellence positions Cutera as an integral player in the medical aesthetics landscape, where it continues to meet the sophisticated demands of both clinicians and patients.

Commitment to Safety and Efficacy

Safety and efficacy remain central to the design of Cutera's devices, which are engineered to deliver predictable outcomes while minimizing risks. The company adheres to strict quality standards and regulatory guidelines, ensuring that every system functions reliably across diverse clinical scenarios. This focus on patient safety and treatment effectiveness is fundamental to its reputation and long-standing trust among practitioners globally.

Comprehensive Support and Market Adaptation

Understanding that innovation alone does not define success, Cutera also invests in comprehensive support systems, ensuring that medical professionals receive continuous training and technical assistance. This approach helps maximize the performance of their devices in clinical settings, thereby reinforcing their commitment to ongoing product development and customer-centric solutions. The company's ability to adapt its product strategies in response to market feedback underlines its expertise and dedication to meeting the evolving needs of the medical aesthetics industry.

Global Influence and Industry Expertise

With direct operations in numerous countries, Cutera leverages its global footprint to steer advancements in the energy-based aesthetics arena. Its international presence not only broadens its market reach but also enhances its capacity for cross-border innovation, enriching the experience and expertise shared within the medical aesthetics community. In doing so, the company provides valuable insights into best practices, industry trends, and technological progress, fostering a collaborative environment that benefits practitioners and patients alike.

Rhea-AI Summary
Cutera, Inc. (Nasdaq: CUTR) received a notice from Nasdaq indicating non-compliance with listing rules due to the inability to file its Form 10-Q for the period ended September 30, 2023. The notice has no immediate effect on the listing or trading of the Company’s securities. Cutera has 60 days to submit a plan to regain compliance, with a possible extension of up to 180 days. However, there is no assurance that Nasdaq will accept the plan, and the Company is working diligently to complete the Form 10-Q.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
none
-
Rhea-AI Summary
Cutera, Inc. (Nasdaq: CUTR) announces the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will lead legal, compliance, intellectual property, and human resources functions, bringing over two decades of legal experience in the life sciences industry. The appointment reflects Cutera's commitment to operational excellence, customer support, and growth of the AviClear franchise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
management
-
Rhea-AI Summary
CUTR - Cutera, Inc. Announces Participation in Upcoming Investor Conferences. Cutera, a leader in aesthetic and dermatology solutions, will have its CEO and VP of Corporate FP&A and Investor Relations participate in fireside chats at three investor conferences. The webcasts will be accessible from the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
conferences
Rhea-AI Summary
Cutera, Inc. (Nasdaq: CUTR) provided preliminary financial results for Q3 2023, including a 26% revenue decrease, and recent business updates. The company announced an enhanced AviClear offering and initiated a global restructuring program expected to save over $20 million in personnel-related expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-42.55%
Tags
-
Rhea-AI Summary
Cutera, Inc. will report Q3 2023 financial results on November 8, 2023. The conference call to discuss the results will be held at 1:30 p.m. PT. Webcast and replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.31%
Tags
-
Rhea-AI Summary
Cutera, Inc. grants inducement awards to new President, International
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.46%
Tags
none
Rhea-AI Summary
Cutera, Inc. appoints Brent Hauser as President, International, effective October 2, 2023. Hauser will be responsible for commercial performance in existing international markets, expansion into new geographies, and the international launch of AviClear in 2024. Hauser brings over 20 years of aesthetics industry experience. Hauser's appointment may lead to growth in international markets and successful launch of AviClear.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.46%
Tags
management
-
Rhea-AI Summary
Cutera launches Secret DUO, a skin resurfacing and revitalization platform with dual non-ablative fractional technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.55%
Tags
none
-
Rhea-AI Summary
Cutera, Inc. approves inducement awards for Chief Operating Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
none
Rhea-AI Summary
Cutera, Inc. appoints Jeff Jones as Chief Operating Officer, emphasizing commitment to product quality and customer service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.73%
Tags
management

FAQ

What is the current stock price of Cutera (CUTR)?

The current stock price of Cutera (CUTR) is $0.0969 as of March 13, 2025.

What is the market cap of Cutera (CUTR)?

The market cap of Cutera (CUTR) is approximately 2.0M.

What is Cutera Inc's core business?

Cutera Inc designs, develops, manufactures, and services energy-based medical aesthetic systems used in procedures such as skin resurfacing, body contouring, and hair removal.

What type of technology does Cutera specialize in?

Cutera is renowned for its advanced laser and optical technologies, including ND:YAG and systems that combine picosecond, nanosecond, and dual-wavelength capabilities for enhanced treatment precision.

How does Cutera generate revenue?

The company generates revenue primarily through the direct sale and servicing of its innovative devices, supported by a robust network of operations in key markets around the globe.

What are the key clinical applications of Cutera's products?

Cutera's devices are used for a variety of medical aesthetic procedures, including acne treatment, body contouring, skin resurfacing, hair removal, and the treatment of benign pigmented lesions and vascular conditions.

How does Cutera ensure patient safety and treatment efficacy?

Safety and efficacy are at the forefront of Cutera's design philosophy. The company adheres to rigorous quality standards and regulatory guidelines to ensure that every device delivers reliable performance in clinical settings.

What distinguishes Cutera from its competitors?

Cutera differentiates itself through its pioneering role in laser technology, its commitment to constant innovation, and its comprehensive support systems that enhance device performance and clinical outcomes.

In which markets does Cutera operate?

Cutera has a strong presence in the United States and operates internationally through direct and allied operations, serving a global network of medical professionals.

How does Cutera support the medical aesthetic community?

The company offers ongoing training, technical support, and product education to ensure that practitioners can maximize device performance and achieve optimal treatment outcomes.
Cutera Inc

Nasdaq:CUTR

CUTR Rankings

CUTR Stock Data

1.96M
19.98M
1.95%
27.66%
19.27%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
BRISBANE